Gabriele Petry

Alfred Nobel Str. 50
Monheim Am Rhein, NW 40789, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications

Field efficacy and safety of Felpreva® (tigolaner, emodepside and praziquantel) spot-on for the treatment of natural ear mite infestations (Otodectes cynotis) and notoedric mange (Notoedres cati) in cats.

Field efficacy and safety of Felpreva® (tigolaner, emodepside and praziquantel) spot-on for the treatment of natural ear mite infestations (Otodectes cynotis) and notoedric mange (Notoedres cati) in cats.

Journal: Current research in parasitology & vector-borne diseases
Published: August 08, 2023

Immediate and long-term efficacy of Felpreva®, a new spot-on formulation containing tigolaner, emodepside and praziquantel, applied as a single application to cats artificially infested with the cat flea Ctenocephalides felis.

Immediate and long-term efficacy of Felpreva®, a new spot-on formulation containing tigolaner, emodepside and praziquantel, applied as a single application to cats artificially infested with the cat flea Ctenocephalides felis.

Journal: Current research in parasitology & vector-borne diseases
Published: April 07, 2023

Efficacy of Felpreva®, a new spot-on formulation containing tigolaner, emodepside and praziquantel, applied as a single application to cats artificially infested with ear mites (Otodectes cynotis).

Efficacy of Felpreva®, a new spot-on formulation containing tigolaner, emodepside and praziquantel, applied as a single application to cats artificially infested with ear mites (Otodectes cynotis).

Journal: Current research in parasitology & vector-borne diseases
Published: April 07, 2023

Multicenter randomized, and blinded European field study evaluating the efficacy and safety of Felpreva®, a novel spot-on formulation containing emodepside, praziquantel and tigolaner, in treating cats naturally infested with fleas and/or ticks.

Multicenter randomized, and blinded European field study evaluating the efficacy and safety of Felpreva®, a novel spot-on formulation containing emodepside, praziquantel and tigolaner, in treating cats naturally infested with fleas and/or ticks.

Journal: Current research in parasitology & vector-borne diseases
Published: March 16, 2022

Multicenter randomized, and blinded European field study evaluating the efficacy and safety of Felpreva®, a novel spot-on formulation containing tigolaner, emodepside and praziquantel, in treating cats with mixed infection with intestinal nematodes, cestodes and/or lungworms.

Multicenter randomized, and blinded European field study evaluating the efficacy and safety of Felpreva®, a novel spot-on formulation containing tigolaner, emodepside and praziquantel, in treating cats with mixed infection with intestinal nematodes, cestodes and/or lungworms.

Journal: Current research in parasitology & vector-borne diseases
Published: March 16, 2022

Efficacy of imidacloprid 10%/moxidectin 1% spot-on formulation (Advocate®) in the prevention and treatment of feline aelurostrongylosis.

Efficacy of imidacloprid 10%/moxidectin 1% spot-on formulation (Advocate®) in the prevention and treatment of feline aelurostrongylosis.

Journal: Parasites & vectors
Published: October 01, 2019

Effectiveness of the spot-on combination of moxidectin and imidacloprid (Advocate®) in the treatment of ocular thelaziosis by Thelazia callipaeda in naturally infected cats.

Effectiveness of the spot-on combination of moxidectin and imidacloprid (Advocate®) in the treatment of ocular thelaziosis by Thelazia callipaeda in naturally infected cats.

Journal: Parasites & vectors
Published: October 08, 2018

Evaluation of the Clinical Efficacy and Safety of a Spot-on Combination of Imidacloprid 10 % / Moxidectin 2.5 % (Advocate®, Advantage® Multi) in Comparison to an Untreated Control Group in the Treatment of Capillaria boehmi in Naturally Infected Dogs.

Evaluation of the Clinical Efficacy and Safety of a Spot-on Combination of Imidacloprid 10 % / Moxidectin 2.5 % (Advocate®, Advantage® Multi) in Comparison to an Untreated Control Group in the Treatment of Capillaria boehmi in Naturally Infected Dogs.

Journal: Parasitology research
Published: July 19, 2017

Evaluation of the Persistent Preventive Efficacy of 2.5 % Moxidectin/10 % Imidacloprid Spot-on (Advocate®, Advantage® Multi) in Dogs Experimentally Infected with Angiostrongylus vasorum.

Evaluation of the Persistent Preventive Efficacy of 2.5 % Moxidectin/10 % Imidacloprid Spot-on (Advocate®, Advantage® Multi) in Dogs Experimentally Infected with Angiostrongylus vasorum.

Journal: Parasitology research
Published: July 19, 2017

Efficacy of moxidectin 2.5% and imidacloprid 10% in the treatment of ocular thelaziosis by Thelazia callipaeda in naturally infected dogs.

Efficacy of moxidectin 2.5% and imidacloprid 10% in the treatment of ocular thelaziosis by Thelazia callipaeda in naturally infected dogs.

Journal: Veterinary parasitology
Published: May 14, 2016

Prevention of Lactogenic Toxocara cati Infections in Kittens by Application of an Emodepside/Praziquantel Spot-on (Profender®) to the Pregnant Queen.

Prevention of Lactogenic Toxocara cati Infections in Kittens by Application of an Emodepside/Praziquantel Spot-on (Profender®) to the Pregnant Queen.

Journal: Parasitology research
Published: July 09, 2015

Evaluation of the Adulticidal Efficacy of Imidacloprid 10 %/Moxidectin 2.5 % (w/v) Spot-on (Advocate®, Advantage® Multi) against Dirofilaria repens in Experimentally Infected Dogs.

Evaluation of the Adulticidal Efficacy of Imidacloprid 10 %/Moxidectin 2.5 % (w/v) Spot-on (Advocate®, Advantage® Multi) against Dirofilaria repens in Experimentally Infected Dogs.

Journal: Parasitology research
Published: July 09, 2015
Showing 1-12 of 17

Last Updated: 09/26/2026